Eupraxia Pharmaceuticals Inc. (EPRX)

Market Cap	103.31M
Revenue (ttm)	n/a
Net Income (ttm)	-28.97M
Shares Out	35.62M
EPS (ttm)	-1.17
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	19,464
Open	2.940
Previous Close	2.920
Day's Range	2.880 - 2.940
52-Week Range	2.480 - 3.500
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About EPRX

Eupraxia Pharmaceuticals Inc., a clinical stage biotechnology company, engages in the discovery, development, and marketing of technologies in the biotechnology sector. The company's lead product candidates are EP-104IAR, which is in a Phase III clinical trial for the treatment of unmet medical needs and for pain relief for knee osteoarthritis; EP-104GI, which is in a Phase II clinical trial for the treatment of eosinophilic esophagitis; and EP-104, under preclinical studies for the treatment of other inflammatory joint conditions, benign struc...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2011
• Employees: 29
• Stock Exchange: NASDAQ
• Ticker Symbol: EPRX

Financial Performance

Financial numbers in USD